Zinit, an AI-native sourcing platform, has raised $8 million in seed funding led by AltaIR Capital. In separate developments, deep-tech healthcare automation company Morphle Labs has raised $5 million from Inflexor Ventures, while biotechnology startup CrisprBits has raised $3 million in a pre-Series A funding round from founders, angels and family offices.
AltaIR Capital leads $8m funding in Zinit
Zinit, an AI-native sourcing platform, has raised $8 million in a seed funding round led by AltaIR Capital, valuing the company at $48 million.
The round also included participation from DVC, early backers of leading AI companies such as Perplexity, who will advise Zinit on its AI strategy.
The new funding will primarily fuel product development and international growth.
In a statement, Zinit said that it is specifically targeting the Indian market’s massive shift toward digital procurement. To spearhead this growth, it has appointed Naveenn Suri as regional director for India. Suri has previously served as a Partner at EY.
As part of this global scaling strategy, Zinit is also aligning its senior leadership in other geographies, including the appointments of Michel Boczko as regional director for Latin America and Stan Moskovtsev (ex-McKinsey) as CEO for the United States.
Morphle Labs secures $5m from Inflexor
Morphle Labs, a Bengaluru-based deep-tech healthcare automation company, has raised $5 million from Inflexor Ventures in its Series A funding round.
The funding will enable the company to accelerate global market expansion, scale manufacturing for its flagship products RoboTome® and MorphoLens, invest in global regulatory approvals, and deepen its technology and IP leadership as it expands into major international markets, the startup said in a statement.
Founded in 2017, Morphle Labs builds next-generation robotic and imaging systems for cancer diagnostics. The company claims to have filed 80+ patents across robotics, optics, embedded systems, and imaging.
“With RoboTome® and MorphoLens, we have tackled two of the most challenging bottlenecks in diagnostics, high-throughput robotic microtomy and robust, modular slide imaging, but this is only the beginning. The larger opportunity lies in stitching together every broken link in the diagnostics chain, enabling labs to deliver faster, higher-quality results and empowering pathologists to focus on what matters most: the diagnosis,” said Rohit Hiwale, Founder & CEO, Morphle Labs.
Spectrum Impact leads funding in CrisprBits
Bengaluru-based biotechnology startup CrisprBits Pvt Ltd has raised $3 million in its pre-Series A funding round through founders, angels and family offices, bringing the company’s valuation to $12 million, per an announcement.
The round was led by Spectrum Impact, the family office of Rajendra Gogri, Chairman and Managing Director of Aarti Industries Ltd.
The round also saw participation from founders and existing investors—Vijay Alreja Family Office (VJ Technologies Group), and new investors, including the promoter family of HBL Engineering Ltd., building upon the earlier funds raised from the founders, VJ Technologies Group and C-CAMP (Centre for Cellular and Molecular Platforms).
The new capital will be deployed to scale commercialisation of the PathCrisp molecular diagnostics platform, augmenting manufacturing capacity for high-impact tests in human health (e.g., sickle cell, typhoid and anti-microbial resistance), food safety, and animal health.
The funding will also accelerate the development of a CRISPR-driven strain engineering platform, starting with the optimisation of processes for biofuel production to address unmet industrial sustainability needs.
